london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Intravitreal ranibizumab in choroidal neovascularisation in children and adolescents

Poster Details

First Author: P.Rao UNITED ARAB EMIRATES

Co Author(s):                      0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

Incidence of choroidal neovascularisation is higher in the aged population and primarily due to age-related macular degeneration. However, this type of neovascularisation is also seen in eyes of young patients because of varied etiology. To describe the etiology, clinical profile and treatment outcomes in eyes with choroidal neovasculrisation (CNV) amongst children and adolescents.

Setting:

Vitreoretinal Services, Mediclinic Welcare Hospital, Dubai.

Methods:

Nine eyes of nine patients less than 18 years of age, diagnosed as CNV were retrospectively reviewed. CNV was diagnosed by clinical examination and confirmed by fundus fluorescein angiography and optical coherence tomography. Snellen’s values for BCVA were converted to logMAR values for statistical calculations. Intravitreal injection of ranibizumab was administered in eyes with active CNV. Anatomical outcome was defined in terms of regressed / persistent / recurrent CNV.

Results:

Seven of the nine patients were male. At presentation, all CNV were active, subfoveal in location and of the “classic” type. Most common cause (66.7%) was post-inflammatory in nature. All eyes showed regression of CNV with a single injection of ranibizumab at the mean follow up of 12.2 months ± 2.8 months.

Conclusions:

CNV is uncommon in children and adolescents however can be a cause of severe visual impairment in this age. In our study, we noted a male predominance, subfoveal location of CNV of “classic” type. These CNV responded well to intravitreal ranibizumab injection and were regressed over the period of one year

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy